Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07174414

Cilostazol for Prevention of Recurrent Stroke Trial

The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Stroke Recurrence Brain Diseases Brain Ischemia Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Heart Diseases Infarction Ischemia Ischemic Attack, Transient Ischemic Stroke Myocardial Infarction Myocardial Ischemia Necrosis Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrent Stroke Stroke Stroke (CVA) or Transient Ischemic Attack TIA (Transient Ischemic Attack) Vascular Death Vascular Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Stanford University

Stanford, California, 94305, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days
  • Currently taking aspirin or clopidogrel (not both) to prevent another stroke

Exclusion criteria

  • Had a spontaneous brain bleed within the last 2 years.
  • Moderate to severe heart failure.
  • Life expectancy is less than 6 months.

Treatment and study plan

Cilostazol 100 mg

Drug

Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.

Placebo

Drug

Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.

Primary outcomes

  1. Major adverse cardiovascular event (MACE)

    Time frame: Up to 4 years after randomization

    Time to stroke (ischemic and hemorrhagic), acute myocardial infarction, or vascular death

Secondary outcomes

  1. Ischemic stroke

    Time frame: Up to 4 years after randomization

    Time to ischemic stroke

  2. Major hemorrhage

    Time frame: Up to 4 years after randomization

    Time to major hemorrhage

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Collaborators

  • Medical University of South Carolina
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • University of Cincinnati
  • Yale University

Registry information

Acronym: Clarity

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Sep 16, 2025
Registry last updated
Sep 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.